Clinical trial · Interventional
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy
NCT05055908CI-TRIAL-00079433BECOMErecruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pembrolizumab | Drug | Pembrolizumab | ALIAS |
| Pemetrexed | Drug | Pemetrexed | ALIAS |
| Pemetrexed plus Pembrolizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cohort A: Chemotherapy plus Immune Checkpoint Inhibitors
- description
- Lung Cancer patients treated with Chemotherapy plus Immune Checkpoint Inhibitors.
- interventionNames
- Drug: Pemetrexed plus Pembrolizumab
- type
- EXPERIMENTAL
- label
- Cohort B: Immune Checkpoint Inhibitors monotherapy
- description
- Lung Cancer patients treated with Immune Checkpoint Inhibitors monotherapy.
- interventionNames
- Drug: Pembrolizumab
- type
- EXPERIMENTAL
- label
- Cohort C: Chemotherapy Group.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form. 2. Age ≥ 18 years. 3. Histologically or cytologically confirmed lung cancer. 4. Treated with Immune Checkpoint Inhibitors with or without chemotherapy. 6\. Predicted survival ≥ 12 weeks. 7. Adequate bone marrow hematopoiesis and organ function 8. Presence of measurable lesions according to RECIST 1.1. Exclusion Criteria: Any conditions can not match for the Inclusion Criteria, includign do not have the data to perform Adverse Events evalutation.
References
Publications (0)
Data not yet available
No reference posted for this study.